Avadel Pharmaceuticals plc (AVDL) Earnings History
Annual and quarterly earnings data from 1996 to 2024
Loading earnings history...
AVDL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AVDL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 91.0% | -25.1% | -28.9% |
| 2023 | 97.0% | -493.0% | -573.2% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | 74.3% | 26.0% | 31.5% |
Download Data
Export AVDL earnings history in CSV or JSON format
Free sign-in required to download data
Avadel Pharmaceuticals plc (AVDL) Earnings Overview
As of May 8, 2026, Avadel Pharmaceuticals plc (AVDL) reported trailing twelve-month net income of -$278,000, reflecting +74.5% year-over-year growth. The company earned $-0.00 per diluted share over the past four quarters, with a net profit margin of -28.9%.
Looking at the long-term picture, AVDL's historical earnings data spans multiple years. The company achieved its highest annual net income of $67M in fiscal 2017.
Avadel Pharmaceuticals plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including JAZZ ($29M net income, -8.3% margin), AXSM (-$188M net income, -28.7% margin), INVA ($504M net income, 63.8% margin), AVDL has room to improve margins relative to the peer group. Compare AVDL vs JAZZ →
AVDL Earnings vs Peers
Earnings metrics vs comparable public companies
AVDL Historical Earnings Data (1996–2024)
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$49M | +69.5% | -$42M | $-0.51 | -28.9% | -25.1% |
| 2023 | -$160M | -16.6% | -$138M | $-2.00 | -573.2% | -493.0% |
| 2022 | -$137M | -77.8% | -$99M | $-2.29 | - | - |
| 2021 | -$77M | -1200.3% | -$86M | $-1.32 | - | - |
| 2020 | $7M | +121.2% | $6M | $0.13 | 31.5% | 26.0% |
| 2019 | -$33M | +65.1% | -$24M | $-0.89 | -56.1% | -40.7% |
| 2018 | -$95M | -241.7% | -$105M | $-2.55 | -92.3% | -101.6% |
| 2017 | $67M | +262.9% | $88M | $1.61 | 38.9% | 51.1% |
| 2016 | -$41M | -201.5% | -$5M | $-1.00 | -27.5% | -3.3% |
| 2015 | $41M | +147.9% | $71M | $0.93 | 23.5% | 41.2% |
See AVDL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVDL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVDL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVDL — Frequently Asked Questions
Quick answers to the most common questions about buying AVDL stock.
Is AVDL growing earnings?
AVDL EPS is $-0.00, with earnings growth accelerating to +74.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-278000.00.
What are AVDL's profit margins?
Avadel Pharmaceuticals plc net margin is -28.9%, with operating margin at -25.1%. Below-average margins reflect competitive or cost pressures.
How consistent are AVDL's earnings?
AVDL earnings data spans 1996-2024. The accelerating earnings trend is +74.5% YoY. Historical data enables comparison across business cycles.